I

I-MAB
D

IMAB

2.31000
USD
0.10
(4.52%)
مفتوح الان
حجم التداول
1,254
الربح لكل سهم
-0
العائد الربحي
-
P/E
-4
حجم السوق
188,635,399
أصول ذات صلة
K
KRYS
0.780
(0.54%)
144.140 USD
M
MNOV
-0.02000
(-1.56%)
1.26000 USD
T
TGTX
1.130
(3.17%)
36.750 USD
المزيد
الأخبار المقالات

العنوان: I/MAB

القطاع: Healthcare
الصناعة: Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).